{"analyses":[{"ciLowerLimit":"2.19","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"22.30","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.029","paramType":"treatment difference in the MMR rate","paramValue":"12.2","statisticalComment":"Stratified by the randomization stratification factor, i.e. cytogenetic response status (MCyR vs no MCyR) at screening","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.48"},{"groupId":"OG001","value":"13.16"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"76"}],"units":"Participants"}],"description":"MMR was defined as a ≥ 3.0 log reduction in BCR-ABL1 transcripts compared to the standardized baseline equivalent to ≤ 0.1% BCR-ABL1/ABL% by international scale (IS) as measured by RQ-PCR.","groups":[{"description":"Participants randomized to asciminib 40mg BID","id":"OG000","title":"Asciminib"},{"description":"Participants randomized to bosutinib 500mg QD","id":"OG001","title":"Bosutinib"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS): The FAS comprised of all randomized participants.","reportingStatus":"POSTED","timeFrame":"24 weeks","title":"Major Molecular Response (MMR) Rate at 24 Weeks","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}